|1.||Diaz, Damaris S: 2 articles (02/2008 - 04/2005)|
|2.||Milhous, Wilbur K: 2 articles (02/2008 - 04/2005)|
|3.||Jacobus, David P: 2 articles (02/2008 - 04/2005)|
|4.||Kozar, Michael P: 2 articles (02/2008 - 04/2005)|
|5.||Shearer, Todd W: 2 articles (02/2008 - 04/2005)|
|6.||Skillman, Donald R: 2 articles (02/2008 - 04/2005)|
|7.||Schiehser, Guy A: 2 articles (02/2008 - 04/2005)|
|8.||Mills, D: 1 article (04/2010)|
|9.||Basak, S C: 1 article (04/2010)|
|10.||Soyinka, Julius Olugbenga: 1 article (02/2010)|
04/21/2005 - "Unlike cycloguanil, however, 1a (WR99210), the active metabolite of 1, has retained in vitro potency against newly emerging antifolate-resistant malaria parasites. "
07/01/1997 - "DHFR gene point mutation as a predictor of Plasmodium falciparum resistance to cycloguanil in malaria cases from Africa imported to France."
04/01/1990 - "Alternative inhibitors, used alone or in combination, may be effective against some strains of cycloguanil- or pyrimethamine-resistant malaria."
04/01/2010 - "Computed molecular descriptors were used to develop quantitative structure-activity relationships (QSARs) for binding affinities (K(i)) for a set of 58 cycloguanil (2,4-diamino-1,6-dihydro-1,3,5-triazine) analogues for dihydrofolate reductase (DHFR) enzyme extracted from wild and A16V+S108T mutant type (a double mutation) malaria parasite Plasmodium falciparum (Pf). "
02/01/2008 - "Unlike cycloguanil, however, WR99210, the active metabolite of PS-15, has retained in vitro potency against newly emerging antifolate-resistant malaria parasites. "
04/01/1999 - "A similarly high antimalarial efficacy against both infections was observed in 62 patients with CYP2C19-related poor metabolizer genotype and in 33 with extensive metabolizer genotype, even though blood cycloguanil was significantly more often detected in those with extensive metabolizer genotype than in those with poor metabolizer genotype. "
01/01/2008 - "However, neither of the Val-16 and Thr-108 mutations, which jointly confer resistance to cycloguanil, was detectable among the human infections. "
07/01/2002 - "All countries of infection considered, the bi-resistance to chloroquine and cycloguanil has not changed from 1996 to 2000. "
06/01/1968 - "Reciprocal cross resistance between cycloguanil hydrochloride and pyrimethamine in Plasmodium berghei infections in mice."
11/01/1980 - "In contrast, parasites of the Liberian I and Haitian I strains, both of which required an adaptive period of a month or longer proved more tolerant to chloroquine, quinine, and cycloguanil but sensitive to pyrimethamine; commonly produced fatal infections in Aotus monkeys, and did not produce demonstrable gametocytemia. "
04/01/1999 - "The results suggest that the parent compound proguanil has significant intrinsic efficacy against falciparum and vivax malaria independent of the metabolite cycloguanil."
04/01/1999 - "Intrinsic efficacy of proguanil against falciparum and vivax malaria independent of the metabolite cycloguanil."
|4.||Falciparum Malaria (Plasmodium falciparum Malaria)
03/01/2006 - "Plasmodium falciparum malaria has no effect on the pharmacokinetic parameters for chlorproguanil, dapsone or chlorcycloguanil. "
04/01/1990 - "Molecular basis of differential resistance to cycloguanil and pyrimethamine in Plasmodium falciparum malaria."
01/01/1984 - "Concomitant resistance to pyrimethamine and cycloguanil of chloroquine-resistant falciparum malaria from East Africa: an in vitro study of 12 isolates."
10/01/2003 - "To determine the pharmacokinetic properties of atovaquone, proguanil, and the triazine metabolite cycloguanil in women with recrudescent multi-drug resistant falciparum malaria during the second and third trimesters of pregnancy treated by artesunate-atovaquone-proguanil. "
12/01/1998 - "Cycloguanil and its parent compound proguanil demonstrate distinct activities against Plasmodium falciparum malaria parasites transformed with human dihydrofolate reductase."
03/01/1996 - "Fifty-eight women who previously took either 200 mg chloroguanide daily (n = 26) or 200 mg chloroguanide daily plus 300 mg chloroquine weekly (n = 32) in a malaria chemoprophylaxis study showed that there was significant correlation between the number of earlier breakthrough parasitemia episodes and the chloroguanide/cycloguanil ratio (rs = 0.30; p = 0.02). "
|2.||Drug Therapy (Chemotherapy)